跳至主要内容
临床试验/NCT03743194
NCT03743194已完成4 期

Pectoralis and Serratus Muscle Blocks for Analgesia After Minimally Invasive Cardiac Procedures

The Cleveland Clinic1 个研究点 分布在 1 个国家目标入组 210 人开始时间: 2021年12月14日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
210
试验地点
1
主要终点
Overall Benefit Analgesia Score

研究概览

简要总结

The overall research plan is PECS/SAP blocks with liposomal bupivacaine improve the Overall Benefit Analgesia Score averaged over the postoperative days 1, 2, and 3. A 20% reduction on geometric means (i.e., true ratio of geometric means of 0.80) in OBAS will be considered the minimal clinically important benefit.

详细描述

The primary aim is to determine whether a PECS/SAP block, using a mixture of bupivacaine and liposomal bupivacaine, provides superior recovery compared to routine parenteral and enteral analgesia in patients recovering from MICS. The primary outcome will be the simple multi-dimensional quality assessment, Overall Benefit Analgesia Score (OBAS score).53 Our secondary aims are to: 1) compare cumulative postoperative opioid consumption (pain medications administered over one-day periods quantified as morphine equivalents and provided by the EMR for the day of surgery and postoperative days 1, 2, and 3; 2) evaluate respiratory mechanics (forced expiratory volume in first minute (FEV1), forced vital capacity (FVC) and peak flow) after extubation on the postoperative days 1, 2 and 3 while patients remain hospitalized; and, (3) evaluate the Quality-of-Recovery-15 score on the postoperative days 1, 2 and 3.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 18-85 years old;
  • Elective minimally invasive robotically-assisted mitral valve repair via anterolateral thoracotomy

排除标准

  • Weight less than 50 kg;
  • Pregnancy or lactation;
  • Emergency surgery and patients transferred from the ICU to the operating room;
  • Redo cardiothoracic surgery or post-operative reoperation within 72 hours of index procedure (including minor chest wall procedures including tube thoracostomy, thoracentesis or percutaneous drain placement);
  • Anticipated endotracheal intubation > 24 hours;
  • Anticipated non-study nerve block that provides analgesia to the intercostal nerves;
  • Active systemic or cardiopulmonary infection;
  • Mechanical circulatory support;
  • Allergy or contraindication to study local anesthetics;
  • Current chronic pain or routine opioid use (patients on chronic enteral opioids like Percocet or Vicodin) in a dose of > 30 mg of morphine-milligram-equivalents for at least 10 days in last 30 days;
  • Poorly controlled psychiatric disorders;
  • Clinically important current neurologic deficit;
  • Active liver disease or cirrhosis;
  • Pacemaker generator or breast implants ipsilateral to surgery;
  • Previous participation in this study.

研究组 & 干预措施

Bupi HCl plus liposomal bupi

Active Comparator

Pectoral fascial plane or serratus anterior plane blocks (PECSII/SAP blocks) with bupivacaine HCl plus liposomal bupivacaine.

An ultrasound guided pectoral fascial plane blocks (PECS I and II blocks) and Serratus anterior plane (SAP) block with injection of the local anesthetic.

干预措施: Exparel 266 MG Per 20 ML Injection (Drug)

Bupi HCl plus liposomal bupi

Active Comparator

Pectoral fascial plane or serratus anterior plane blocks (PECSII/SAP blocks) with bupivacaine HCl plus liposomal bupivacaine.

An ultrasound guided pectoral fascial plane blocks (PECS I and II blocks) and Serratus anterior plane (SAP) block with injection of the local anesthetic.

干预措施: Placebo (Drug)

Control Group

Placebo Comparator

Standard parenteral analgesia technique with or without incisional local anesthetic infiltration: patients randomized to control group will be given parenteral opioids (such as fentanyl or hydromorphone) until they are converted to the enteral medications such as Percocet.

干预措施: Placebo (Drug)

结局指标

主要结局

Overall Benefit Analgesia Score

时间窗: Postoperative day 1-3

Our primary outcome, Overall Benefit Analgesia Score (OBAS), was measured daily by investigators blinded to treatment on postoperative Days 1 to 3.Potential scores of the seven-item questionnaire ranged from 0 to 28 points. Higher scores means worse conditions.

次要结局

  • Postoperative FEV1(Postoperatively day 1 -3)
  • Cumulative Opioid Consumption Over Postoperative 3 Days(72 hours postoperative)
  • Postoperative FVC(Postoperative day 1 -3)
  • Postoperative Peak Flow(Postoperative day 1-3)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验